BioMimetic Therapeutics  
Worldwide
 
Overview
 

Company News

FDA rejection of Augment graft improves future for smaller companies (August 12, 2013)
Medtech M&A on course for the worst year in a decade (July 25, 2013)

Displaying 5 out of a possible 225 unique stories.
Results Sorted By date


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile 01 MAR 2013: Wright Medical Group acquired BioMimetic Therapeutics for $380m or $12.97 per share, based on Wright’s closing stock price on 16 NOV 2012.

BioMimetic Therapeutics (BMTI) was a Tennessee based biotechnology company focused on development & marketing of clinically proven products to promote the healing of musculoskeletal injuries & diseases, including therapies for orthopaedic & sports medicine applications.
Listed or Private Company Listed
Company Classification Specialty (Pharma); Biotechnology; MedTech
Country USA
Company Website
Technology Platform Profile Regenerative technology:
Promotes tissue healing and regeneration by combining rhPDGF-BB with tissue specific matrices, when appropriate.
Full Company Profile Information

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
BioMimetic Therapeutics 1 12

Note: Daily share prices and certain other per-share data are supplied to EvaluatePharma Ltd by a third party and under the terms of supply are available for on-screen viewing purposes only. Copying these data out of EvaluatePharma is not permitted and such data are masked within downloads into Excel (TM).


Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now